Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Idorsia Pharmaceuticals Ltd

Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension
From Idorsia Pharmaceuticals Ltd
Via GlobeNewswire
TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension
From Idorsia Pharmaceuticals Ltd
Via GlobeNewswire
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension
From Idorsia Pharmaceuticals Ltd
Via GlobeNewswire
US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement
From Idorsia Pharmaceuticals Ltd
Via GlobeNewswire
Idorsia and Viatris enter into a significant global research and development collaboration
From Idorsia Pharmaceuticals Ltd
Via GlobeNewswire
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
From Idorsia Pharmaceuticals Ltd
Via GlobeNewswire
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023
From Idorsia Pharmaceuticals Ltd
Via GlobeNewswire
On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder
From Idorsia Pharmaceuticals Ltd
Via GlobeNewswire
Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension
From Idorsia Pharmaceuticals Ltd
Via GlobeNewswire
Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs
From Idorsia Pharmaceuticals Ltd
Via GlobeNewswire
Idorsia announces financial results for the first half 2022 – reaching commercial stage
From Idorsia Pharmaceuticals Ltd
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.